This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Consensus Guidelines in the Treatment of Major Depressive Disorder

A. John Rush, M.D.; M. Lynn Crismon, Pharm.D.; Marcia G. Toprac, Ph.D.; Madhukar H. Trivedi, M.D.; William V. Rago, Ph.D.; Steve Shon, M.D.; and Kenneth Z. Altshuler, M.D.

Published: July 1, 1998

Article Abstract

The number of available antidepressant medications has increased dramatically in the last 10years. Furthermore, no single medication is a panacea for all depressed patients—a fact underscoredby randomized, controlled trial evidence showing that when one medication fails, an alternative maysucceed. Thus, a key issue in the treatment of depression is how to optimally orchestrate availablemedication options to maximally benefit the greatest number of patients most rapidly. One approach isthe use of consensus guidelines or medication algorithms. This paper discusses the rationale for andcritical issues in the development of medication algorithms, and the timely use of symptom measuresto ensure proper implementation. Once developed, guidelines must be appropriately implemented byclinicians, adhered to by patients, and supported by administrators. These three stakeholder groupsoften need education, incentives, and ongoing support to implement such guidelines. Whether guidelinesactually improve outcome is largely uninvestigated, although a recent study of depressed patientsin primary care found that using guidelines did improve outcome but at an increased treatmentcost. The clinical and economic impact of guideline-driven treatment for the severe and persistentlydepressed deserves study.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...

Read More...